Delivery Order SPE2DB22D9207-SPE2DB24FH5AW

Award Date 5/28/24
Potential Completion Date 6/18/24
Potential Value $40K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,131.04 contract is to provide Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,065.52 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vials. This delivery order is issued under DMS Pharmaceutical Group's larger $4,999,999 indefinite delivery contract with DLA to provide a broad range of pharmaceutical products, including prescription drugs, vaccines,...
The U.S. Defense Logistics Agency (DLA) awarded a $40,142.85 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract provides the Keytruda 100 mg/4 ml vial medication, with a period of performance running through May 14, 2024. This delivery order is placed against DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, which...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $80,218.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which is not set-aside, is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $47,990.80, is for the supply of Keytruda 100 mg/4 ml vials to fulfill the recurring pharmaceutical supply needs of military health facilities. This delivery order is issued under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,131.04 firm fixed-price contract is for the delivery of Keytruda 100 mg/4 ml vials. This order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to issue delivery orders for a wide range of...
The U.S. Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $80,285.70 order is for Keytruda 100 mg/4 ml vial 4 ml, and is part of a larger indefinite delivery contract (DLA Contract 4600082013) held by DMS Pharmaceutical Group with a potential value up to $4,999,999 through the end of 2025. This single-award contract enables DLA to issue delivery orders for a wide...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $80,285.70, is for the delivery of 4,566,364,793 units of Keytruda 100 mg/4 ml vial (4 ml) to support the recurring medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC)...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $127,565.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Keytruda 100 mg/4 ml vials, a cancer medication, with a period of performance through October 16, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $40,109.20, is a firm fixed-price delivery order for Keytruda 100 mg/4 ml vials. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, that runs through December 31,...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB24FH5AW
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,109.20 contract is for the supply of Keytruda 100 mg/4 ml vial (4 ml) to support the medical needs of military healthcare facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to $499,999,999, that allows the DLA to issue orders for a wide range of pharmaceutical products through December 31, 2025. The contract has no set-aside designation.

Generated 8/27/24, 10:07 AM